Actinogen Medical Limited · ASX:ACW
Actinogen Medical — Bioshares Biotech Summit 2026
17 slides from Actinogen Medical's conference presentation, Aug 6, 2026
Slide 1: ASX Announcement: Actinogen presents corporate presentation at Bioshares
ASX ANNOUNCEMENT Actinogen presents a brief corporate presentation highlighting the Company, Xanamem and its strong scientific rationale in Alzheimer’s disease based on human cortisol literature Sydney, 06 August 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce the 12
Slide 2: About Actinogen Medical and clinical trials
Investors Media Dr Steven Gourlay Michael Roberts George Hazim CEO & Managing Director Communications Media & Public Af f airs Australia P: +61 2 8964 7401 M: +61 423 866 231 M: +61 417 516 262 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au E: georgehazim@mediaaffairs.com.au
Slide 3: Xanamem clinical experience and disclaimer
Chronically elevated cortisol is associated with progression in Alzheimer’s Disease and excess cortisol is known to be toxic to brain cells. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials. The recent
Slide 4: Advancing oral Xanamem in Alzheimer's Disease
For personal use only Advancing oral Xanamem® in Alzheimer’s Disease Topline data from phase 2b/3 pivotal trial in November (n=247) Potentially game-changing product profile Strong scientific rationale for brain cortisol as a therapeutic target Corporate Presentation, Bioshares 2026 August 6, 2026 ®
Slide 5: Disclaimer
Disclaimer This presentation is dated June 2026 and has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all infor
Slide 6: Corporate and Xanamem highlights
Corporate and Xanamem highlights Potentially game-changing oral therapy in late-stage trials for Alzheimer’s disease Validated 11β-HSD1 mechanism with differentiated oral profile NEXT MAJOR VALUE INFLECTION For personal use only • Xanamem is a novel oral therapy targeting elevated brain cortisol, a
Slide 7: Why do we believe brain cortisol control with Xanamem can slow Alzheimer's disease?
For personal use only Why do we believe brain cortisol control with Xanamem can slow Alzheimer’s disease (AD)? Corporate Presentation Bioshares August 2026 4
Slide 8: Cortisol and the Alzheimer's brain
Cortisol and the Alzheimer’s brain “Stress” and/or genetic factors may drive multiple AD mechanisms via cortisol For personal use only Xanamem’s target: Genetic alternations are both protective (down) and a risk factor (up) for cognitive decline Seckl J 2024 (left panel); Milligan Armstrong et al. 2
Slide 9: Elevated human brain cortisol levels linked to AD
Elevated human brain cortisol levels linked to AD Brain fluid cortisol measurements best reflect the tissue cortisol environment For personal use only German Dementia Competency Network study 0.7 p<0.001 0.6 0.5 CSF cortisol (μg/dl) 0.4 0.3 0.2 0.1 0 Cognitive Normal MCI Other MCI AD AD dementia Pop
Slide 10: ApoE4 risk factor associated with elevated brain cortisol levels
Major AD genetic risk factor of ApoE4 associated with elevated brain cortisol levels ~67% of patients in AD trials have one or two copies of the ApoE4 gene For personal use only a) CSF cortisol level by disease classification (SCI: subjective cognitive impairment; SMCI stable mild cognitive impairme
Slide 11: Therapeutic cortisol worsened AD over months
Therapeutic cortisol worsened AD over 12 months Historical trial of 10mg prednisolone in patients with mild to moderate disease (n=138) For personal use only 9 8 7 Placebo Prednisolone (cortisol) 6 Point 5 Change In 4 Score Worsening 3 2 1 0 Cognition Dementia Depression ADAS-cog CDR-SB Ham-D P=0.16
Slide 12: Cortisol excess is toxic to the brain
Cortisol excess is toxic to the brain Literature from clinical use as a therapeutic and excess cortisol in Cushing’s syndrome For personal use only Symptom or sign of brain toxicity Trends to worsening Alzheimer’s disease Shrinkage to hippocampus General brain shrinkage Memory impairment Executive f
Slide 13: Xanamem achieves high brain target occupancy
Xanamem achieves high brain target occupancy Distribution of cortisol synthesis enzyme 11β-HSD1 shown in left panel For personal use only Baseline After 7 days of daily dosing 5 mg Xanamem 10 mg Xanamem 20 mg Xanamem SUVRcarotid Reduction in tracer signal (loss of color) indicates high 11β-HSD1 occu
Slide 14: Xanamem data in patients with mild Alzheimer's
Xanamem data in patients with mild Alzheimer’s Phase 2a data showed slowing of decline over 12 weeks (n=34 with high pTau181) For personal use only Xanamem Placebo 0 0.2 0.4 0.36 0.6-point benefit @12 weeks CDR-SB* units 0.6 Xanamem vs. Placebo Change from • Mean 0.6 units Baseline (SE) 0.8 • Median
Slide 15: Durable activity in phase 2 depression trial
Durable activity in phase 2 depression trial Separation from placebo overall and on background SSRI therapy For personal use only Baseline Week 2 Week 4 Week 6 Week 10 0 -2 PT 4.2-point difference Cohen’s d = 0.64 EOT 2.6-point difference p = 0.03 -4 Cohen’s d = 0.38 from baseline (± SE) p = 0.15 LS
Slide 16: What we hope to see in November
What we hope to see in November: much greater ability to slow disease than existing treatments 0.5 SIMULATED PHASE 2B/3 DATA For personal use only Xanamem phase 2a p- 0 Worsening of tau–positive patients CDR-SB showed near- -0.5 over 18 months stabilization -1 -1.5 Modest benefit -2 of donanemab (Ki
Slide 17: Contacts
Contacts For personal use only Will Souter Steven Gourlay CFO & Investor Relations CEO & Managing Director M: +61 402 035 716 P: +61 2 8964 7401 E. will.souter@actinogen.com.au E. steven.gourlay@actinogen.com.au Join the Actinogen Investor Hub: https://investors.actinogen.com.au/ Corporate Presentat